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We describe a case of infective endocarditis due to Neisseria elongata, and review the
literature. N. elongata is a constituent of the normal oral flora and a rare cause of infective
endocarditis. Unfamiliarity with the organism and its rod-shaped morphology may lead
to a delay in microbiological diagnosis. Although the organism is relatively sensitive to
antibiotics, our experience in the management of the described case and a review of
previous reports suggest that antibiotic therapy alone may not be sufficient. It is likely
that patients with N. elongata endocarditis will require surgery.
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I N T R O D U C T I O N
Neisseria elongata is a constituent of the commensal
bacterial flora in the pharynx. Its phylogenetic
classification places it alongside the cocci, but it
is rod-like in morphology [1]. It was previously
thought to be non-pathogenic, but has relatively
recently been found to cause infective endocarditis
(IE) and osteomyelitis [2,3]. Normal, diseased and
bioprosthetic valves have all been affected in cases
of endocarditis. Although cases have been
reported in the USA, Europe, Canada, and Aus-
tralia, we describe here what is probably the first
reported case of N. elongata endocarditis in the UK.
C L I N I C A L S U M M A R Y
A 54-year-old-male presented with a 2-week history
of fever, rigors, headache, anorexia and non-
productive cough. He had had a similar, self-limit-
ing illness for about a week 4 months previously.
There was a history of travel to Malaysia just
before this earlier illness. He had also had dental
treatment (scaling) around the same time,
although this was not recalled until later. There
was no known previous cardiac pathology.
On examination the patient had rigors with a
temperature up to 40 8C. His heart rate was 96
beats/min; blood pressure, 125/70 mmHg; and
respiratory rate, 24/min. Heart sounds were nor-
mal, with no murmurs. There was no evidence of
cardiac failure, and there were no peripheral stig-
mata of IE. His chest and abdomen were otherwise
normal, as were neurologic examinations. There
was no arthritis or meningism. Urinalysis revealed
traces of blood and protein. Laboratory tests
showed raised C-reactive protein (234 mg/L, nor-
mal range <10 mg/L) and evaluated white cell
count (20 109/L). Other laboratory tests, includ-
ing blood films for malarial parasites, were unre-
markable.
Three sets of blood cultures were taken at the
time of admission, and the patient was treated
with intravenous ceftazidime, 2 g 8-hourly. Within
24 h, an organism with the appearance of Gram-
negative bacilli was grown from the aerobic bottles
of all three blood cultures (Figure 1). The organism
grew as dry colonies on blood and MacConkey
agars after incubation in CO2 at 37 8C. It was
oxidase positive and catalase negative. Antibiotic
susceptibility was determined by E test (Cam-
bridge Diagnostics Services, Cambridge, UK).
The organism had reduced sensitivity to penicillin
(MIC 0.125 mg/L) and trimethoprim (MIC 1 mg/
L), but was fully sensitive to amoxicillin (MIC
0.032 mg/L), gentamicin (MIC 0.032 mg/L), cefur-
oxime (MIC 0.25 mg/L), ceftazidime (MIC 0.5 mg/
L), and ciprofloxacin (MIC 0.002 mg/L). The Cen-
tral Public Health Laboratory, Colindale, UK later
confirmed the organism as N. elongata subsp.
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nitroreducens, using a combination of fatty acid
analysis (analysis done on The Sherlock Microbial
Identification Systems, MIDI, Inc., Newark, DE,
USA) and biochemical tests. The organism was
glucose negative and reduced nitrate and nitrite. A
positive nitrate reduction result differentiates
between N. elongata subsp. nitroreducens and other
N. elongata subspecies.
The patient’s fever defervesced within 48 h.
Despite clinical review and ultrasound of his abdo-
men, the source of infection remained unidentified
until 6 days after admission, when an ejection
systolic murmur was heard. An additional early
diastolic murmur was noted on the following day.
Transesophageal echocardiography (Figure 2)
showed a bicuspid aortic valve with a vegetation
on the anterior leaflet. There was transvalvular
leak across the aortic valve. No aortic root abscess
was seen. The antibiotic treatment was continued,
as the patient’s clinical response appeared satis-
factory.
However, the patient started to experience some
chest discomfort and dizziness 1 week later. This
progressed to breathlessness. Clinical and radio-
graphic examination revealed overt pulmonary
edema. Gentamicin was added to the treatment,
and the patient was transferred to a cardiothoracic
center on the same day. Attempts were made to
stabilize his condition, but in light of the worsen-
ing transvalvular leak, surgical intervention was
required within 48 h.
At operation, the patient was found to have an
aortic root abscess, and underwent a prosthetic
aortic valve replacement. The excised valve and
swabs from the abscess were sterile on extended
culture for 4 weeks. The valve was not sent for
histopathologic examination. Intravenous ceftazi-
dime and gentamicin were continued for 4 weeks
after surgery, and the patient made a full recovery.
D I S C U S S I O N
N. elongata was described by Bøvre and Holten in
1970 as a rod-shaped member of the family Neis-
seriaceae [1]. Later workers reported isolates of
CDC group M-6, now known as N. elongata subsp.
nitroreducens, as early as 1964 [2]. It is closely
related to Kingella and Moraxella spp. [4,5]. It
now contains three subspecies, N. elongata subsp.
elongata, N. elongata subsp. glycolytica, and N. elon-
gata subsp. nitroreducens. Of these, N. elongata
subsp. nitroreducens is most frequently associated
with invasive disease. This organism is non-
motile, oxidase positive, catalase negative, and
reduces nitrates [2,6]. The majority of strains grow
on blood agar, producing non-hemolytic colonies
which are 1–2 mm in diameter.
Although there is no apparent reason for any
specific geographic distribution of N. elongata, it is
interesting that there are no previous published
reports of infections with the organism in the UK;
nor are there notifications to the Communicable
Diseases Surveillance Center, Colindale, UK. This
may reflect either a lack of awareness or difficulties
in microbiological identification.
The diagnosis of our patient was complicated by
the rarity of the pathogen, history of recent travel
to South East Asia, and absence of obvious risk
factors for IE.
We have reviewed previous reports of N. elon-
gata endocarditis in the literature [2,5–15]. Delay in
Figure 1 Gram stain of Neisseria elongata showing Gram-
negative, rod-shaped organisms.
Figure 2 View of the left ventricular outflow tract seen in
the horizontal plane (1208) on transesophageal echocardio-
graphy. A vegetation can be seen on the non-coronary cusp
of the aortic valve.
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Table 1 Summary of previous reported cases of N. elongata endocarditis fulfilling the Duke criteria. The top line refers to the case presented
Ref. Age
Duration of,
illness,
prior to
admission
Murmur at
presentation
Murmur
during
illness
No. of
positive
blood
cultures
Dukes
echocardiographic
criteria Risk factors Complications Subspecies Surgery
This
case
54 2 weeks No Yes 3 of 3 Veg. on AV, AR,
abscess
Bicuspid AV,
dental
procedure
CHF; aortic
root and
myocardial
abscess
nitroreducens AVR
[7] 50 Not specified No No Not specified Veg. on
prosthetic AV
Prosthetic AV CVA;
myocardial
abscess
nitroreducens AVR
[8] 29 >3 weeks No Yes 3 of 5 Veg. on MV, MR None Brachial
pseudoaneurysm
glycolytica
(G1018)
Removal of
pseudoaneurysm
[9] 74 1 month No No 19 of 24 None Prosthetic AV,
dental
infection
None noted nitroreducens None
[10] 31 1 month No No 2 of 2 Veg. on MV None None noted nitroreducens None
[6] 57 Not specified Yes Yes 6 of 6 Veg. on AV, AR None None noted – None
[11] 27 3 weeks No Yes Not specified MVP MVP, dental
abscess
Splenic
infarction;
late CHF
nitroreducens MVR
[12] 33 2 weeks No Yes 3 of 3 Veg. on AV, AR,
abscess
Bicuspid AV,
dental
procedure
Aortic root
abscess with
myocardial fistula
nitroreducens AVR and
pericardial
patch
[13] 82 2 weeks Yes Yes 4 of 5 MR, Veg. on MV Dental
procedure
CHF; renal
failure
nitroreducens MVR
[2] 25 2 weeks No Yes 6 of 6 MR None Confusion;
CHF; renal
failure
nitroreducens MVR
[2] 31 Not specified Yes Yes Not specified Veg. on MV None CVA nitroreducens MV
debridement
[14] 65 1 week Yes Yes Not specified AR, MR None TTP; confusion nitroreducens None
[5] 31 3 weeks Yes Yes 6 of 6 Veg. on MV Gingivitis,
dental
procedure
Renal failure;
myocardial
abscess
nitroreducens MVR
[15] 57 1 month Yes Yes 11 of 11 None Rheumatic
heart disease,
previous
endocarditis
CHF nitroreducens AVR
AV, aortic valve; MV, mitral valve; AR, aortic regurgitation; MR, mitral regurgitation; MVP, mitral valve prolapse; AVR, aortic valve replacement; MVR, mitral valve
replacement; CHF, congestive heart failure; TTP, thrombotic thrombocytopenic purpura; CVA, cerebrovascular accident; Veg., vegetation.
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diagnosis due to difficulty in identifying the
organism, or absence of a murmur at presentation,
was a feature common to several cases. Tables 1
and 2 present a summary of the salient features of
14 cases meeting the Duke criteria for IE [16].
Several cases have been reported to the Centers
for Disease Control, Atlanta, USA, but have not
been described in the literature [2]. One case of N.
elongata septicemia in a patient with hypertrophic
obstructive cardiomyopathy did not meet the
Duke criteria [4].
Nearly all of the cases in Table 1 presented with
typical symptoms of IE, namely fever, malaise,
arthralgia, headache, and weight loss. One excep-
tion was a 31-year-old male who presented with a
possible cerebrovascular accident [2]. The dura-
tion of symptoms prior to presentation was
usually 2–3 weeks, and at least nine of the 14 cases
did not have a murmur at presentation. Eight
patients had some identifiable risk factor for endo-
carditis. Echocardiographic findings included ten
patients with a vegetation and nine with regurgi-
tation through the diseased valve. Other cardiac
complications included four patients with heart
failure and four with localized abscess formation.
Cerebral embolization (two cases), acute renal fail-
ure (three cases) and thrombocytopenic purpura
(one case) were also reported. All cases were
treated with either ampicillin or a third-generation
cephalosporin, often in combination with genta-
micin. Eight cases (57%) proceeded to valve repla-
cement surgery (Table 2).
N. elongata is an uncommon cause of endo-
carditis. Clinicians and microbiologists should
be aware that, despite belonging to the genus
Neisseria, the organism is a Gram-negative rod
rather than a coccus. This organism is associated
with endocarditis and osteomyelitis [17]. Thus the
Table 2 Summary of the antibiotic treatment in previously reported cases of N. elongata endocarditis fulfillling the Duke
criteria. The top line refers to our case
Ref. Antibiotic therapya Daily dose Duration of therapy MIC (mg/L)
This case Ceftazidime 6 g 7 weeks 0.5
Gentamicin 240 mg 4 weeks (after week 3) 0.032
[7] Ampicillin – 6 weeks –
[8] Ceftriaxone 2 g 6 weeks 0.06
Gentamicin 200 mg 6 weeks 0.12
[9] Ampicillin 12 g 6 weeks 0.47
Gentamicin 160–240 mg 2 weeks 4.0
[10] Ampicillin – Not specified –
Gentamicin – Not specified –
Ceftriaxone – 4 weeks –
[6] Penicillin G 24 MU 5 weeks –
Gentamicin 240 mg 5 weeks –
[11] Ceftriaxone 2 g 6 weeks –
Gentamicin 280 mg 3 weeks –
[12] Penicillin 24 MU 9 days ? 0.12
Ampicillin 12 g 4 weeks (after day 9) 0.06
Gentamicin 120 mg >4 weeks 1.00
[13] Ceftazidime – 10 days –
Ampicillin 12 g >4 weeks (after day 10) –
Gentamicin – 16 days –
[2] Nafcillin – Changed to penicillin –
Penicillin – Not specified –
Gentamicin – Not specified –
[2] Nafcillin – ? 9 weeks –
Ampicillin – ? 9 weeks –
Gentamicin – ? 9 weeks –
[14] Ceftriaxone – 4 weeks –
[5] Penicillin G 24 MU 2 days –
Gentamicin 300 mg 2 days <0.25
Ampicillin 12 g 4 weeks (after day 2) <0.125
[15] Tobramycin – 25 days –
Ampicillin – 7 weeks –
aIn many cases, several antibiotics were used. The table includes only those used with therapeutic benefit in each case.
 2003 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 9, 426–430
Concise Communication 429
presence of N. elongata in blood cultures should
lead the clinician to consider these diagnoses.
Furthermore, the review of the literature in con-
junction with our case suggest that endocarditis
caused by N. elongata commonly requires early
surgical intervention.
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